$0.20
(Market cap
$535 Mln
Recently Viewed
Clear AllMarket cap
$535 Mln
Revenue (TTM)
$175 Mln
P/E Ratio
--
P/B Ratio
4.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
26.9
Debt to Equity
2
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
86,876,549
CFO
€-242.92 Mln
EBITDA
€-273.37 Mln
Net Profit
€-488.56 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Valneva SE - ADR
| -38.2 | -47.2 | -47.1 | -20.0 | -20.4 | -- | -- |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Valneva SE - ADR
| 101.7 | -57.5 | -18.5 | -77.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Valneva SE - ADR
|
5.5 | 535.3 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 4.1 |
| 22.8 | 12,698.2 | 19,628.0 | 978.0 | 9.1 | 6.8 | 11.5 | 0.8 | |
| 28.9 | 1,966.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.1 | 0.5 | |
| 1.4 | 155.8 | 2.8 | -47.2 | -86.4 | 734.6 | -- | 20.1 | |
| 5.3 | 1,177.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 33.9 | 1,638.7 | 29.6 | -24.0 | -- | 31.9 | -- | 65.0 |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for... active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France. Read more
President, CEO & Director
Mr. Thomas Lingelbach
President, CEO & Director
Mr. Thomas Lingelbach
Headquarters
Saint-Herblain
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Valneva SE - ADR is $5.45 (NASDAQ) as of 23-Apr-2026 11:36 EDT. Valneva SE - ADR has given a return of -20.39% in the last 3 years.
Since, TTM earnings of Valneva SE - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Valneva SE - ADR are Rs 12.25 and Rs 5.22 as of 23-Apr-2026.
Valneva SE - ADR has a market capitalisation of $ 535 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Valneva SE - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.